REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

The Myriad Way

Peter D Meldrum, CEO of the genetics company on battles about patents, licensing, cancer chips, and competitors in commercial academia

(C) B2Bioworld 2012 - Peter D. MeldrumMarch 2012. Myriad Genetics’ offerings are contentious, in particularly when it comes to patent protection of  genes – once in Europe, now in the U.S. In the exclusive interview with B2Bioworld, Peter Meldrum, CEO and co-founder of the Utah-based company describes expansion plans with biomarker services. He takes a stand on clinical DNA chips, and answers reproaches of patenting human genes, blocking scientific research, or pursuing a strangling licence policy for those laboratories willing to make breast cancer or colon carcinoma tests more widely available to patients. What will be Myriad’s course after Mr. Meldrum reaches retirement age next June?

 

Related Articles

Improving the IP System on a global scale: A view from Japan

Prof. Sadao Nagaoka, Institute of Innovation Research, and Chief Policy Adviser to the Japanese Government

Systems Biology Applied

The Need of Systems Theory Thinking in Using Technologies and Pitfalls of Some Concepts. Prof. Rudi Balling, Luxembourg Centre for Systems Biomedicine

Customs Sequencing Markets

Worldwide evolution of the market and upcoming business opportunities, incl. Illumina

Stem Cells: a discovery tool and a potential therapeutic modality

Dr Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – including: a non-trivial concept of personalised medicine

Patenting Stem Cells – Behind the Front Stage

System Biology: In search of good questions 

Prof. Walter Kolch on the approach taken by Systems Biology Ireland

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

 




If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

6 pages, advert-free

Roche tender offer for Illumina, Inc: $44.50 per share in cash

27-01-2012. Roche announced today that it has commenced a cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ILMN). The offer and withdrawal rights are scheduled to expire at 12:00 midnight, New York City time, at the end of the day on February 24, 2012, unless the offer is extended. Under the terms of the offer, Roche is offering to acquire Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis. This offer represents a premium of 64% over Illumina’s closing stock price on December 21, 2011 – the day before market rumors about a potential transaction between Roche and Illumina drove Illumina’s stock price significantly higher – a 61% premium over the one-month historical average and a 43% premium over the three-month historical average of Illumina’s share price, both as of December 21.


Roche’s offer is conditional upon, among other things, (i) the tender by Illumina’s stockholders prior to the expiration of the tender offer of a number of shares, which, together with the shares owned by Roche, represents at least a majority of the total number of shares outstanding on a fully diluted basis, (ii) the redemption of the preferred stock purchase rights associated with the shares or Roche’s satisfaction in its reasonable discretion that such rights have been invalidated or are otherwise inapplicable to the tender offer and the proposed merger, (iii) Roche’s satisfaction that the anti-takeover provisions of the Delaware General Corporation Law are inapplicable to the proposed merger and (iv) Illumina must not have entered into or effectuated any agreement or transaction with any person or entity having the effect of impairing Roche’s ability to acquire Illumina or otherwise diminishing the expected value to Roche of the acquisition of Illumina. If following the consummation of the offer Roche owns at least a majority of the outstanding

Source: Roche

 

__________________

Disclaimer: You agree that  B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on   B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by  B2Bioworld.

 

___________________

Related Articles

by B2Bioworld  

Customs Sequencing Markets

Worldwide evolution of the market and upcoming business opportunities, including Illumina

Roche Ethiopia: Build-up of an emerging market

We need the users, and users have to adopt it

A Global View on Interconnectivity, Quality, Harmonisation of Standards of Laboratory Automation and Biomanufacturing

Everyone re-invents the wheel

Michael Collasius, Vice President Automated Systems Qiagen NV, on industry-wide standards for laboratory instruments

Stem Cells: a discovery tool and a potential therapeutic modality

Dr Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research. Leveraging different methods and technologies.

Handling Suppliers of Mass Spectrometers Delicately

 

 

Top 10 Tags

All Tags (2094)